TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01228305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children \>=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to \<2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children \>=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to \<2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
Study: NCT03688022

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: MT-7117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: MT-7117

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI
Description: Proton pump inhibitor

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acidic beverage
Description: Acidic beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acidic beverage
Description: Acidic beverage
Study: NCT00410423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib with mitoxantrone, etoposide and cytarabine
Description: All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0mg/m^2
Description: All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3mg/m^2
Description: All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
Study: NCT02650206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Victoza (liraglutide) with dietician monitoring
Description: Victoza (liraglutide), an FDA-approved medication, is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Subjects with this intervention will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with dietician monitoring
Description: Subjects will not receive the study drug, but will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
Study: NCT01209286

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous intravenous infusion over four weeks per treatment cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous intravenous infusion over four weeks per treatment cycle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous intravenous infusion over four weeks per treatment cycle
Study: NCT01920178

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PinPointe Foot Laser
Description: Active Laser Treatment Group will receive active Pinpointe Foot Laser beam. Control Placebo Sham Laser Group will receive only the localizing (aiming) non-active beam of the Pinpointe Foot Laser

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PinPointe Foot Laser
Description: Active Laser Treatment Group will receive active Pinpointe Foot Laser beam. Control Placebo Sham Laser Group will receive only the localizing (aiming) non-active beam of the Pinpointe Foot Laser
Study: NCT04252170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation Therapy, Experimental on the BrightArm Compact device
Description: Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). An Occupational Therapist will assist as needed.
Study: NCT02218775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2456302
Description: Mood and Anxiety Disorders
Study: NCT01808521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: IV administration of N-Acetylcysteine at 150mg/kg over 60 min first, then if well tolerated, 150mb/kg over 17 hours
Study: NCT02245750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: hysteroscopy and endometrial injury prior to the IVF/ICSI cycle
Study: NCT04208321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as matching tablets (to 40 mg and 80 mg VT-1598 tablets) containing the inactive components of VT-1598.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as matching tablets (to 40 mg and 80 mg VT-1598 tablets) containing the inactive components of VT-1598.
Study: NCT04255654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Intervention for Food Insecurity
Description: 2 item screening tool (brief intervention)
Study: NCT01708005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lecitone®Se-Vitamin D3
Description: Lecitone®Se-Vitamin D3 is a dietary supplement combining the active ingredients in Lecitone®Se and 100 IU of vitamin D3. This dietary supplement comes in capsule form.~Participants take 2 capsules of Lecitone®Se -Vitamin D3 per day. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The comparator is represented by placebo capsules of identical appearance (same size, same color and same smell) that Lecitone®Se-Vitamin D3 capsules.
Study: NCT01068223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A:JNJ-39758979/Placebo #1
Description: Single oral dose of JNJ-39758979 600 mg and Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C:Cetirizine/JNJ-39758979 Matching Placebo
Description: JNJ-39758979 Matching Placebo and Placebo #2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B: JNJ-39758979 Matching Placebo /Placebo #2
Description: A single dose of 2 different Placebos
Study: NCT00984698

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Rhythm Group Therapy
Description: 12 weeks, 2h structured group therapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Group Therapy
Description: 12 weeks, 2h relatively unstructured group therapy
Study: NCT00847158

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification alone
Description: phacoemulsification alone

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent Trabecular Micro-Bypass Stent
Description: phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
Study: NCT05211453

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: atrioventricular node ablation
Description: atrioventricular node ablation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: atrioventricular node ablation
Description: atrioventricular node ablation
Study: NCT00596258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-007
Description: applied topically for two 28-day cycles of 14 consecutive days of treatment each to the uterine cervix
Study: NCT01372683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Comparison of oat based breakfast cereals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Comparison of oat based breakfast cereals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Comparison of oat based breakfast cereals
Study: NCT00246610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir mesylate, 625 mg
Description: Nelfinavir 625 mg \[dosed orally as 1250 mg BID (two 625 mg tablets given orally BID)\] plus Combivir (lamivudine 150 mg plus zidovudine 300 mg BID dosed orally) administered with food. Subjects will start treatment at their baseline visit. Subjects will be treated for up to 26 weeks during pregnancy plus 6 weeks postpartum.
Study: NCT04445519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCX 470 0.065% (initial phase of trial)
Description: NCX 470 Ophthalmic Solution, 0.065% (initial phase of trial)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% (initial phase of trial)
Description: Latanoprost Ophthalmic Solution, 0.005%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCX 470 0.1% (initial phase of trial)
Description: NCX 470 Ophthalmic Solution, 0.1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCX 470 0.1% (remainder of trial)
Description: NCX 470 Ophthalmic Solution, 0.1%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% (remainder of trial)
Description: Latanoprost Ophthalmic Solution, 0.005%
Study: NCT04208321

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as matching tablets (to 40 mg and 80 mg VT-1598 tablets) containing the inactive components of VT-1598.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as matching tablets (to 40 mg and 80 mg VT-1598 tablets) containing the inactive components of VT-1598.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as matching tablets (to 40 mg and 80 mg VT-1598 tablets) containing the inactive components of VT-1598.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1598
Description: VT-1598 is a novel oral agent for the treatment of fungal infections. It will be supplied as 40 mg and 80 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1598
Description: VT-1598 is a novel oral agent for the treatment of fungal infections. It will be supplied as 40 mg and 80 mg tablets.
Study: NCT01683643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT
Description: Screening, brief intervention, and referral to treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
Study: NCT00961610

Intervention type: BEHAVIORAL
Intervention: Internet peer-support group
Description: The Internet peer-support groups provided a self-guided space for communication, including an Internet discussion forum, a live chat room and a personal message system. No therapeutic content or information services were offered within the groups.~All Internet groups were run in a browser-based software platform with access through the website of the Danish Cancer Society (http://www.cancer.dk). All discussions were protected by a password and communication was encrypted.~The Internet groups in this study were all closed peer-support groups, accessible only by an invitation received by e-mail after registration for the study. The groups were open to access 24 h a day for 13 months from their individual starting date.

Intervention type: BEHAVIORAL
Intervention: Internet peer-support group
Description: The Internet peer-support groups provided a self-guided space for communication, including an Internet discussion forum, a live chat room and a personal message system. No therapeutic content or information services were offered within the groups.~All Internet groups were run in a browser-based software platform with access through the website of the Danish Cancer Society (http://www.cancer.dk). All discussions were protected by a password and communication was encrypted.~The Internet groups in this study were all closed peer-support groups, accessible only by an invitation received by e-mail after registration for the study. The groups were open to access 24 h a day for 13 months from their individual starting date.
Study: NCT04208321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1598
Description: VT-1598 is a novel oral agent for the treatment of fungal infections. It will be supplied as 40 mg and 80 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1598
Description: VT-1598 is a novel oral agent for the treatment of fungal infections. It will be supplied as 40 mg and 80 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1598
Description: VT-1598 is a novel oral agent for the treatment of fungal infections. It will be supplied as 40 mg and 80 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1598
Description: VT-1598 is a novel oral agent for the treatment of fungal infections. It will be supplied as 40 mg and 80 mg tablets.
Study: NCT03542591

Intervention type: OTHER
Intervention: Questionnaire on the topic Supplementation of critical nutrients in a plant-based diet
Description: No active intervention, only survey as mentioned above.
Study: NCT02167048

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psychostimulants
Description: Participants will be tested twice 2 weeks apart. All will continue on their normal Psychostimulant dose up until 3 days before the testing day. 3 days before their 1st testing session, half the participants will start on either their current-dose of Psychostimulant or half their current dose depending on the arm they were randomized to (we provide those pills).~To control for different pharmacokinetics of the Psychostimulant medications, a given participant will be tested at roughly the peak time for his/her specific version of Psychostimulant and at the same time of day for his/her two testing sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychostimulants
Description: Participants will be tested twice 2 weeks apart. All will continue on their normal Psychostimulant dose up until 3 days before the testing day. 3 days before their 1st testing session, half the participants will start on either their current-dose of Psychostimulant or half their current dose depending on the arm they were randomized to (we provide those pills).~To control for different pharmacokinetics of the Psychostimulant medications, a given participant will be tested at roughly the peak time for his/her specific version of Psychostimulant and at the same time of day for his/her two testing sessions.
Study: NCT01040923

Intervention type: DEVICE
Intervention: CardioSond Cardiac Sonospectrographic Analyzer
Description: The CardioSond is a completely noninvasive, FDA 510(k) cleared digital electronic stethoscope designed to detect heart sounds and murmurs using ultrasensitive acoustic technology.
Study: NCT01792778

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ViaValve Safety IV Catheter
Description: Insertion of the peripheral intravenous catheters into both upper extremities of subjects

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insyte Autoguard BC [Blood Control] Shielded IV Catheter
Study: NCT03936764

Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative Pulmonary Rehabilitation
Description: Each prehabilitation session will last approximately 90 minutes and will include:~* Endurance training at the ventilatory threshold, determined according to the initial CPET. The first session will last for 15 to 20 minutes then increase by 5 minutes each session to reach 45 minutes in total (including a 5-minute warm-up and 5 minutes of active recovery). The intensity will then increase by 5 or 10 W, as could be tolerated;~* Peripheral muscle strengthening at 60% to 70% of the 1-repetition maximum of 3 main components (quadriceps press, whole-leg extension, and upper limb pull down). Three sets of 12 movements will carry out for each exercise and the load will increase weekly as tolerated;~* Inspiratory muscle training using a threshold calibrated to at least 30% of the MIP. Patients will be encouraged to carry out 15 minutes of independent training daily and to increase the resistance regularly.~* Education to bronchial drainage techniques as well as directed coughing.

Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative Pulmonary Rehabilitation
Description: Each prehabilitation session will last approximately 90 minutes and will include:~* Endurance training at the ventilatory threshold, determined according to the initial CPET. The first session will last for 15 to 20 minutes then increase by 5 minutes each session to reach 45 minutes in total (including a 5-minute warm-up and 5 minutes of active recovery). The intensity will then increase by 5 or 10 W, as could be tolerated;~* Peripheral muscle strengthening at 60% to 70% of the 1-repetition maximum of 3 main components (quadriceps press, whole-leg extension, and upper limb pull down). Three sets of 12 movements will carry out for each exercise and the load will increase weekly as tolerated;~* Inspiratory muscle training using a threshold calibrated to at least 30% of the MIP. Patients will be encouraged to carry out 15 minutes of independent training daily and to increase the resistance regularly.~* Education to bronchial drainage techniques as well as directed coughing.
Study: NCT00949221

Intervention type: DEVICE
Group type: OTHER
Intervention: monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE
Description: * group 1: continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months;~* group 2: intensive strategy using continuous glucose monitoring for 12 months;~* group 3: intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring).

Intervention type: DEVICE
Group type: OTHER
Intervention: monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE
Description: * group 1: continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months;~* group 2: intensive strategy using continuous glucose monitoring for 12 months;~* group 3: intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring).

Intervention type: DEVICE
Group type: OTHER
Intervention: monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE
Description: * group 1: continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months;~* group 2: intensive strategy using continuous glucose monitoring for 12 months;~* group 3: intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring).
Study: NCT03524950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Ninety patients will be assigned to three groups. Group A add saline in general anesthesia laparoscopic hysteromyoma surgery. Group B add dexmedetomidine 1μg/Kg10minutes as loading dose, followed by 0.7μg/Kg/h for maintenance.Group C add dexmedetomidine 0.7μg/Kg10minutes as loading dose, followed by 0.5μg/Kg/h for maintenance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Ninety patients will be assigned to three groups. Group A add saline in general anesthesia laparoscopic hysteromyoma surgery. Group B add dexmedetomidine 1μg/Kg10minutes as loading dose, followed by 0.7μg/Kg/h for maintenance.Group C add dexmedetomidine 0.7μg/Kg10minutes as loading dose, followed by 0.5μg/Kg/h for maintenance.
Study: NCT01203956

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartFlex
Description: Device used with smartflex engaged.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Study: NCT02176902

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary intervention
Description: Receive dietary counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary intervention
Description: Receive guidelines for low-fat diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03630965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPR Video
Description: A 7.07 minutes' CPR video will be administered to the ICU patients' surrogates in Group B.~After viewing the video, the surrogate will complete the Hamilton Anxiety Rating Scale, a five-question survey about CPR, and a one-question form about comfort using the Likert Scale.
Study: NCT03408821

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem Solving Therapy (PST)
Description: Participants will attend 8 weekly session of Case Manager (CM) implemented PST, a form of group talk therapy.
Study: NCT05011617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-intubation and monitoring anesthesia care (MAC)
Description: Non-intubation and monitoring anesthesia care (MAC) consisted of non-intubation technique, local anesthesia at the site of sternotomy, sedation with dexmedetomidine, analgesia with remifentanil/sufentanil, and electroacupuncture.
Study: NCT00312845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib + Rituximab
Description: VELCADE for Injection will be administered weekly on Days 1,8,15, and 22 of a 35-day cycle in combination with 4 doses of rituximab once a week on Days 1,8,15, and 22 of Cycle 1 and in combination with a single dose of rituximab on Day 1 of Cycles 2 to 5.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: rituximab once a week on Days 1,8,15, and 22 of Cycle 1, and as a single dose on Day 1 of Cycles 2 to 5 (for a total of 8 doses).
Study: NCT02659384

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atezolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo